$328.80-0.31% today
AI Take · AlgoThesis
Amgen's RSI of 35.3 signals deep oversold territory—a rare alignment for a $189B heavyweight that typically commands premium valuations. Trading at a 22.8x P/E with only 2.36% short interest suggests the selloff reflects genuine sector headwinds rather than a squeezable position. The biotech giant sits well below its 52-week high, creating a technical disconnect between its quality fundamentals and current price action. This combination hints at either capitulation exhaustion or justified caution about near-term catalysts and pipeline confidence.
Snapshot
Market cap
$189.2B
P/E
22.8
Forward P/E
14.7
EPS (TTM)
$14.38
Dividend yield
2.91%
Net margin
21.0%
ROE
89.4%
RSI (14)
35
Beta
0.61
Short % of float
2.4%
Days to cover
4.7
52w high
No
Recent headlines
Peers in Biological Products, (No Diagnostic Substances)
Build a thesis around AMGN
Type a thesis in plain English. AlgoThesis researches it with real data, cites sources, and hands back a tradeable basket.
Open in AlgoThesis →